Recipharm invests in Analytical Development Services
Facility in Solna, Sweden, is set for significant capacity expansion
4th December 2012: Recipharm has today announced a significant strategic investment to expand capacity in analytical services and stability studies at its facility in Solna, Sweden. The facility is equipped with advanced laboratories and technology for pharmaceutical formulation as well as a GMP suite for development and manufacturing of sterile and non-sterile clinical trial materials.
It will now be reconstructed to facilitate expansion of analytical development within the Recipharm group. "This is a very important step for us as increasing this capacity will enable the company to enhance the high quality services to our customers", says Maria Lundberg, General Manager at Recipharm Pharmaceutical Development. "Our analytical development service is already an integrated and vital part of the pharmaceutical development work, and this investment will enable our business to continue to grow, creating more flexibility and a better service offering. We are convinced that it is vital to small and large Pharma companies that competent service partners can supply high quality pharmaceutical development services including high quality analytical development.
Analytical services normally included in the pharmaceutical offering comprise: development and validation of stability indicating analytical methods, supply and execution of method transfer protocols, establishment of new product assay and degradation methods, graduated validation plans to suit the phase of drug development, cleaning validation, report writing and of course stability studies according to ICH. This expansion will mean that Recipharm will have the capability to support more projects in parallel with these services.
The analytical lab in Solna will be ready and fully compliant with ICH, EU and FDA GMP in May 2013.
Notes to editors
Recipharm AB is a leading contract development and manufacturing organisation
(CDMO) based in Sweden employing some 1,700 employees. The Company
operates development and manufacturing facilities in Sweden, France, the UK, Germany and Spain and is headquartered near Stockholm. Recipharm supplies the global pharmaceuticals market with hundreds of different products in multiple dosage forms that include solid dose, granulates and powders, sterile liquids and lyophilisates, semi solids, beta-lactams, hormones, oral liquids, sprays and dry powder inhalers.
Recipharm's Pharmaceutical Development Services group offer services from straight forward manufacture of clinical trial material through to more complex product development and formulation. From our pharmaceutical development centre we can work on a variety of technologies, including sterile products. Formulation development, analytical method development and stability studies are all core activities.
For more information visit; www.recipharm.com
Recipharm – Maria Lundberg, General Manager, +46 8 602 52 73
For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: E-mail: [email protected] or a.heele[email protected]
Tel: +44 (0) 207 861 3019/3043
CONFIDENTIALITY NOTICE AND LEGAL LIABILITY WAIVER: The content of this email and any attachments are CONFIDENTIAL and may contain privileged information. If you are not the addressee it may be UNLAWFUL for you to read, copy, distribute, disclose or otherwise use the information contained herein. The content of the message and or attachments may not reflect the view and opinions of the originating company or any party it is representing.
If you are NOT the intended recipient then please email back to [email protected]